Last reviewed by Dr. Dharmender Malik on 7 May 2026. Reflects current Second Read service workflow and pricing at FMRI Gurgaon.
Introduction
The patient sits in the consultation room with a stack of papers in his lap. The PET-CT was done last week at a centre near home, and the report is in his hand. He has read it three times. He understands some of the words. "Increased FDG uptake in the right paratracheal lymph node, suggestive of metastatic involvement." What he does not know — what he came to find out — is whether that sentence means the next step is surgery, radiation, chemotherapy, all three, or watchful waiting. The oncologist has given him a plan. He wants to be sure the plan is built on solid ground.
This is the moment a PET scan second opinion is for. Not for second-guessing every report. Not for shopping until you find the answer you want. For the specific moment when a major treatment decision is about to be built on top of an imaging report — and you, or your treating doctor, want a second pair of expert eyes on the study before that decision is final.
What a PET scan second opinion actually is
A PET scan second opinion — sometimes called a Second Read — is an independent review of an existing PET-CT study by a different nuclear medicine physician. The original DICOM image dataset is uploaded along with the original report, and a sub-specialty-trained reader reviews the entire study from scratch, then writes a structured second-opinion report. The second read can confirm the original findings, identify additional findings the first reader missed, or correct interpretation errors that change the clinical picture.
Importantly, a second read is not a re-scan. The patient is not re-injected, not re-imaged, not re-irradiated. The image data already exists. What is being reviewed is the interpretation. This is part of why second reads are accessible — financially and practically — and why they are increasingly part of best practice in oncology imaging worldwide.
A useful frame
A PET-CT report is not a fixed object. It is a physician's interpretation of complex three-dimensional imaging data. Two trained readers can look at the same study and produce reports that differ — sometimes in ways that matter clinically. Published inter-reader concordance studies in oncology imaging suggest meaningful disagreement in 5–15% of cases, depending on tumour type, scan type, and reader experience.[1] A second read does not assume the first read was wrong. It assumes that high-stakes decisions deserve high-confidence interpretation.
Why expert reads matter — particularly for niche tracers
For a standard FDG PET-CT in lymphoma or lung cancer, an experienced general nuclear medicine reader at a well-equipped centre will produce a report that meets the clinical need in most cases. The argument for sub-specialty review becomes much stronger for tracers and tumour types where reading expertise is scarcer. PSMA PET in prostate cancer, DOTANOC or DOTATATE PET in neuroendocrine tumours, FAPI PET across multiple solid tumours — these are studies where the difference between an experienced reader and an occasional one can be meaningful.
The reason is partly volume and partly biology. PSMA-avid lesions in the bone, for example, can be confused with degenerative changes by a reader who has not seen many hundreds of these scans. DOTANOC studies require an understanding of physiological uptake patterns in the spleen, pituitary, and pancreatic uncinate process that takes years to develop. FAPI PET is a newer tracer where most readers are still building their interpretation library. In each of these areas, sub-specialty reading reduces the chance of a missed finding and reduces the chance of a false-positive that triggers unnecessary intervention.
FMRI's Nuclear Medicine team has read more than 30,000 PET-CT studies over the past two decades, with particularly deep volume in PSMA, DOTANOC, and FAPI. That is the practical answer to "why FMRI for a Second Read". We are not the only sub-specialty centre in India, but for these specific tracers we have built one of the largest institutional reading volumes available.
When you should actually consider a Second Read
Not every PET-CT needs a second opinion. The cases where second reads add the most clinical value tend to fall into three patterns:
Before a major treatment decision is finalised
A second read makes the most sense when a high-stakes clinical decision is about to be built on the scan: planning a major surgery, radiation field design, starting first-line systemic therapy, or — particularly relevant for our patient population — deciding whether a patient is a candidate for PSMA radioligand therapy. The cost of a Second Read is a tiny fraction of the cost of a wrong treatment plan.
When the report is ambiguous, or contradicts the clinical picture
If your treating doctor reads the report and says "this doesn't quite fit what we're seeing clinically", that is a strong signal for a second read. Sometimes the imaging is right and the clinical picture is incomplete. Sometimes the report missed a finding that explains the discrepancy. A sub-specialty reader can adjudicate.
When the scan was performed at a centre without sub-specialty expertise
This applies most strongly to niche tracers. PSMA PET-CT and DOTANOC PET-CT are performed at many centres in India today, but the reading expertise is not evenly distributed. If a PSMA PET was performed in a city or centre where sub-specialty PSMA reading volume is low, a Second Read at a high-volume centre is a reasonable safeguard before treatment is built on top of it.
And one pattern where a Second Read is not usually the right move: when the patient is dissatisfied with the clinical plan and is hoping a different report will produce a different recommendation. Imaging does not change to fit the answer the patient wants. If the original report is sound and the recommendation that follows from it is sound, a second read will most often confirm both, not change them. That is its purpose.
"A Second Read does not assume the first read was wrong. It assumes that decisions taken on top of imaging reports — especially before surgery, radiation, or systemic therapy — deserve high-confidence interpretation."
How the Second Read service at FMRI works
Infographic · The Process
From your study to a structured second read, end‑to‑end, in 48 hours.
30,000+PET reads · 20 yrs
48hrStandard turnaround
₹ 2,500Indian study fee
DICOMCalibrated workstation
-
01
Submit
Upload DICOM dataset and original report via secure portal.
T + 0
-
02
Triage
Routed to the sub‑specialty reader matched by tracer and tumour type.
T + 4 hr
-
03
Read
Independent interpretation on a calibrated workstation, blinded to the original.
T + 24 hr
-
04
Report
Structured comparison report — confirmed, additional and divergent findings.
T + 48 hr
-
05
Consult
Optional 15‑min video call with the reading physician.
Optional
Sub‑specialty triage routes by tracer
PSMA PETProstate cancer
DOTANOC PETNeuroendocrine tumours
FAPI PETMulti‑tumour novel tracer
FDG PETLymphoma · lung · H&N
Ready to request a Second Read?
Standard turnaround 48 hours. Indian study fee INR 2,500 (approx USD 100). International study fees vary by complexity and are confirmed before reading begins.
Start Second Read
What you receive — and what to do with it
The Second Read report is not a replacement for the original report. Both reports remain in the patient's record. Most referring oncologists welcome the additional read; in our experience, the structured comparison format we use makes the report easier to act on rather than harder. The receiving clinician can see at a glance which findings were confirmed, which were added, and which were re-interpreted, with imaging references for each.
What you do with the report depends on what it says. If the Second Read confirms the original interpretation, the value is reassurance — the treatment plan can proceed with higher confidence. If the Second Read identifies additional findings, the next step is usually a brief discussion between the patient, the referring oncologist, and (if needed) the reading physician to integrate the new information into the plan. If the Second Read substantially differs from the original interpretation, the typical next step is a multidisciplinary discussion — sometimes with a third read at a tertiary academic centre — before any treatment decision is finalised.
That last scenario is uncommon but it does happen. When it does, the existence of the Second Read often prevents a poorly-informed treatment plan from being implemented. That is the point.
A closing thought
A second opinion on imaging is an underused tool in oncology, partly because patients do not know it is available, partly because the workflow at most centres has not been built to make it easy. We have tried to build it to make it easy: secure upload, sub-specialty triage, structured report, transparent pricing, 48-hour turnaround. The point is not to replace the relationship between a patient and the imaging team that did the original scan. It is to add a layer of expert review at the moments where the stakes are highest.
If you are facing a major treatment decision in the next few weeks, and that decision is being built on a recent PET-CT, ask yourself two questions. First: is the centre that read the scan a high-volume centre for this specific tracer and tumour type? Second: how much would a second pair of expert eyes change my confidence in the plan? If the answer to the first is "not really" and the answer to the second is "meaningfully", a Second Read is probably worth the modest cost. Patients who do this in our experience walk into their next oncology appointment with greater clarity. That is what the service is built to provide.
Citations & references
Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53(7):1041-1047. (Inter-reader variability in PET interpretation discussion.)
Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328-354.
Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466-1486.
Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588-1601.
FMRI Nuclear Medicine institutional volume data — internal records, current as of May 2026 (cumulative PET-CT reads since service inception). For peer-reviewed publications, see
our publications page.
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York
Director & Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited. Two decades of sub-specialty PET-CT reading with one of the largest institutional volumes in PSMA, DOTANOC, and FAPI tracers in India. Lead reader on the FMRI Second Read service.